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ABSTRACT
The expression and function of the skeletal muscle
chloride channel CLCN1/ClC-1 is regulated by alter-
native splicing. Inclusion of the CLCN1 exon 7A
is aberrantly elevated in myotonic dystrophy (DM),
a genetic disorder caused by the expansion of a
CTG or CCTG repeat. Increased exon 7A inclusion
leads to a reduction in CLCN1 function, which can
be causative of myotonia. Two RNA-binding protein
families—muscleblind-like (MBNL) and CUG-BP and
ETR-3-like factor (CELF) proteins—are thought to
mediate the splicing misregulation in DM. Here, we
have identified multiple factors that regulate the
alternative splicing of a mouse Clcn1 minigene.
The inclusion of exon 7A was repressed by MBNL
proteins while promoted by an expanded CUG
repeat or CELF4, but not by CUG-BP. Mutation
analyses suggested that exon 7A and its flanking
region mediate the effect of MBNL1, whereas
another distinct region in intron 6 mediates that of
CELF4. An exonic splicing enhancer essential for the
inclusion of exon 7A was identified at the 5’ end of
this exon, which might be inhibited by MBNL1.
Collectively, these results provide a mechanistic
model for the regulation of Clcn1 splicing, and
reveal novel regulatory properties of MBNL and
CELF proteins.
INTRODUCTION
Myotonic dystrophy (dystrophia myotonica, DM) type 1,
or DM1, is a genetic disorder with multi-systemic
symptoms, such as myotonia, progressive muscle loss,
cataracts, cardiac conduction defects, insulin resistance
and cognitive impairments (1). DM1 is caused by the
expansion of a CTG trinucleotide repeat in the
30-untranslated region (UTR) of the DM protein kinase
(DMPK) gene (2–4). Evidence suggests that the expanded
CUG repeats transcribed from a mutated allele cause
RNA gain-of-function eﬀects that aﬀect the function of
other cellular factors. This concept is supported by
transgenic mice (HSA
LR) expressing an expanded CUG
repeat inserted in an unrelated gene (human skeletal
actin, HSA) that manifest myotonia and abnormal
muscle histology (5). Recently, a second locus of DM
has been identiﬁed, and CCTG repeat expansion in
intron 1 of the ZNF9 gene was found to be causative of
DM type 2 (DM2; 6). Remarkably, in the nuclei of cells of
patients with both DM1 and DM2, RNA inclusions
containing CUG and CCUG repeats, respectively, have
been observed (6–8). In addition, abnormalities in RNA
metabolism have been found in the cells of DM patients.
Splicing of certain genes is misregulated in DM1. These
genes include cardiac troponin T (cTNT/TNNT2), insulin
receptor (IR), chloride channel 1 (CLCN1), fast skeletal
troponin T (TNNT3), sarcoplasmic/endoplasmic
reticulum Ca
2+-ATPase (SERCA) 1 and others (9–14).
The splicing patterns of some of these genes are also
misregulated in DM2 patients and the HSA
LR mouse
(12,15,16). These results suggest that certain RNA-
binding proteins that regulate pre-mRNA splicing
of these genes are abnormally inﬂuenced by the
mutant transcripts containing expanded CUG/CCUG
repeats (17).
Two protein families—muscleblind-like (MBNL) and
CUG-BP and ETR-3-like factor (CELF) proteins—may
play major roles in the pathogenesis of DM. MBNL
proteins MBNL1/EXP, MBNL2/MBLL/MLP1 and
MBNL3/MBXL/CHCR are orthologs of the Drosophila
muscleblind protein, which is involved in the terminal dif-
ferentiation of photoreceptor and muscle cells in the ﬂy
(18,19). All three MBNL proteins can colocalize with
RNA inclusions of expanded CUG/CCUG repeats in
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both CUG and CCUG repeat RNA in a length-dependent
manner in vitro (21,22). Therefore, these proteins are con-
sidered to be sequestered by the expanded RNA through
direct interactions, and their cellular functions can be dis-
rupted in both types of DM. Remarkably, knockout mice
of Mbnl1 manifest some DM-like symptoms, including
myotonia, abnormal muscle histology and cataracts (13).
More recently, Mbnl2 knockout mice were reported to
manifest myotonia (23). Importantly, cellular studies
have demonstrated that MBNL proteins can directly
regulate the alternative splicing of the cTNT and IR
genes, which are misregulated in DM1 patients (24,25).
These results strongly support the hypothesis that loss of
function of MBNL proteins leads to the misregulation of
splicing in DM.
CELF proteins are another protein family involved
in the pathogenesis of DM1. CELF proteins CUG-BP/
CUGBP1/BRUNOL2, ETR-3/CUGBP2/NAPOR/
BRUNOL3, CELF3/TNRC4/BRUNOL1, CELF4/
BRUNOL4, CELF5/BRUNOL5 and CELF6/
BRUNOL6 are multi-functional proteins that play regu-
latory roles in translation, RNA editing, mRNA stability,
as well as splicing (26–29). CUG-BP regulates the alterna-
tive splicing of cTNT exon 5, IR exon 11 and CLCN1
intron 2 (9–11). In DM1 patients, the expression of
CUG-BP protein is elevated because of protein stabiliza-
tion induced by PKC-mediated phosphorylation
(10,30,31). Moreover, CUG-BP transgenic mice can
reproduce some of the muscular abnormalities observed
in DM1 or its congenital form, including aberrant splicing
and muscle histology (32,33). CUG-BP acts antagon-
istically against MBNL proteins in the splicing regulation
of cTNT and IR (24,25), suggesting that altered CELF
activities, in addition to the loss of MBNL function, can
induce aberrant splicing in DM1. However, the extent
to which these proteins can account for splicing
abnormalities and the pathogenesis of DM remains
unclear.
Myotonia is a characteristic symptom of both DM1 and
DM2 and has been linked with a loss of function of
CLCN1 chloride channel caused by aberrant splicing
of its pre-mRNA in DM patients (11,12). The CLCN1
protein is a muscle-enriched voltage-gated chloride
channel and is important for stabilizing the resting poten-
tial of muscle membrane (34). More than 50 mutations of
CLCN1 have been found in myotonia congenita, another
genetic disorder with myotonia, directly linking defects of
CLCN1 with the pathogenesis of myotonia (35). In DM1
patients, the abnormal inclusion of alternative exons 6B
and/or 7A and retention of intron 2 of CLCN1 have been
observed (11,12). These aberrant-splicing patterns can
lead to CLCN1 transcripts containing premature termina-
tion codons, resulting in an enhanced degradation of
transcripts through the mechanism of nonsense-mediated
mRNA decay (NMD), or the production of truncated
proteins having a dominant-negative eﬀect (12,36).
Consistently, the levels of CLCN1 mRNA and protein
are considerably lower in the muscle of DM patients
(11,12). Thus, the misregulated splicing of CLCN1 in
DM1 leads to a reduction in CLCN1 activity, which can
be causative of myotonia.
In mouse models expressing an expanded CUG repeat
(HSA
LR) or lacking Mbnl1, the inclusion of exon 7A in
mouse Clcn1 increased, as in human CLCN1 of DM
patients (12,13). It is important to note that the intro-
duction of exogenous MBNL1 into HSA
LR mice by
viral administration reversed the misregulation of
Clcn1 splicing as well as the myotonic phenotype (37).
Furthermore, antisense oligonucleotide (AON)-induced
exon 7A skipping resulted in the upregulation of Clcn1
mRNA and protein levels and eliminated myotonia in
both HSA
LR and Mbnl1 knockout mice (38). This
suggests that the misregulation of Clcn1 splicing alone
can explain the pathogenesis of myotonia in these mouse
models. Therefore, MBNL proteins play an essential role
in the splicing regulation of Clcn1 and are probably
involved in the pathogenesis of myotonia in DM.
Although the loss of function of MBNL was reproduced
in these two mouse models, another pathogenic pathway
involving CELF proteins might have been under-
represented in these models, which did not show
elevated CUG-BP protein levels (13,16,39). Therefore, it
is important to ask whether CELF proteins are involved in
the regulation of CLCN1/Clcn1 splicing. Indeed, CUG-BP
binds directly to an element in intron 2 and promotes the
retention of this intron (11). Furthermore, CUG-BP
transgenic mice exhibit increased inclusion of Clcn1 exon
7A, even though the manifestation of myotonia is not
clear (33). Thus, it is important to characterize the roles
of MBNL and CELF proteins in the regulation of Clcn1
splicing to understand the mechanism of myotonia in DM.
Although increased exon 7A inclusion is the most frequent
abnormality of CLCN1/Clcn1 splicing in DM (12), the
mechanism of its regulation is still unclear.
We established a Clcn1 minigene assay system and
identiﬁed multiple cis- and trans-acting factors that
regulate the alternative splicing of Clcn1 exon 7A. The
essential role of MBNL proteins in the normal splicing
pattern of Clcn1 was veriﬁed. Our results also highlight
some CELF proteins as antagonistic regulators against
MBNL proteins.
MATERIALS AND METHODS
cDNA clones and constructs
MBNL1 and MBNL2 were ampliﬁed by polymerase chain
reaction (PCR) from a human skeletal muscle cDNA
library (BD Marathon-Ready human cDNA; Clontech).
MBNL3 was ampliﬁed from a human liver cDNA library.
Because the ampliﬁed MBNL3 cDNA clones contained an
extra exon compared to a previous MBNL3 sequence, this
exon was deleted by PCR-mediated mutagenesis. CELF
proteins ETR-3, CELF3, CELF4, CELF5 and CELF6
were ampliﬁed from cDNA libraries of either brain or
skeletal muscle of human origin. CUG-BP was ampliﬁed
from pSRD/CUG-BP (40). Forward primers for the
ampliﬁcation of these cDNAs contained BamHI, BglII,
or EcoRI sites, whereas the reverse primers contained
either SalI or XhoI sites to add these restriction sites to
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inserted into the BamHI-XhoI or EcoRI-XhoI site of
pSecDK, a mammalian expression vector with a myc-tag
that was modiﬁed from pSecTagA (Invitrogen) to delete
the Igk chain leader sequence. Constructs encoding GST-
MBNL140 has been described previously (22). The Clcn1
minigene fragment covering exons 6 to 7 was ampliﬁed
from mouse genomic DNA by PCR using the primer
pair Clcn1-Fw and Clcn1-Rv, into which a restriction
site for BamHI or SalI was added. Similarly, the corre-
sponding fragment of human CLCN1 was ampliﬁed using
primers CLCN1-Fw and CLCN1-Rv. The minigene
fragments were ligated into pGEM-T Easy vector
(Promega). The minigene fragments in pGEM-T Easy
were cleaved by BamHI and SalI and then subcloned
into the BglII-SalI site of pEGFP-C1 (Clontech). A
series of deletion mutants of Clcn1 was generated by
PCR-mediated mutagenesis. To construct heterologous
minigenes, we inserted alternative exons with ﬂanking
regions such as Clcn1 451–720 into the BglII-SalI sites
of pEGFP-Tpm2-ex1-2 vector (see Supplementary
‘Materials and Methods’ section). Primer sequences are
listed in Supplementary Table S1. Detailed information
on the sequences and construction of mutant minigenes
is available upon request. DM18 and DM480 contain a
fragment of the 30 region of DMPK with a CTG18 and
interrupted CTG480 repeats, respectively (Supplementary
Figure S4).
R-miR, a vector modiﬁed from pcDNATM6.2-GW/
EmGFP-miR (Invitrogen), was utilized for RNA interfer-
ence (RNAi) experiments. R-miR contains a cDNA
fragment of monomeric RFP (mRFP) in place of
EmGFP and an Esp3I recognition site introduced down-
stream of mRFP. DNA fragments corresponding to a
portion of an artiﬁcial microRNA (Supplementary
Table S2) were designed using BLOCK-iT RNA
Designer (Invitrogen website) and inserted into the
Esp3I site of R-miR.
The FANTOM3 clone plasmids encoding murine
Mbnl3 (E430034C16), Cugbp1 (4432412L08), Cugbp2/
Etr-3 (9530098D08) and Celf4 (C130060B05) used for
testing RNAi eﬃciency in Neuro2a cells were provided
by Dr Hayashizaki (41). Murine Mbnl1 and Mbnl2
were ampliﬁed from a mouse brain cDNA library. The
N-terminal regions of Mbnl1, Mbnl2 and Mbnl3 and the
full-length open reading frames of Cugbp1, Cugbp2 and
Celf4 were ampliﬁed with primers containing restriction
sites, digested by the restriction enzymes, and inserted
into the BglII-SalI site of the pEGFP-C1 vector. All
constructs were conﬁrmed by sequencing.
Cellular splicing assay
Cells transfected with plasmids for the expression of a
protein and a minigene were harvested 48h post-
transfection. Typically, cells were cultured in 12-well
plates and transfected with 0.5mg plasmids for protein
expression (or cognate empty vector) and 0.01mg
plasmids for the expression of a minigene. Total RNA
was extracted and puriﬁed using either the acidic
guanidine phenol chloroform method or RNeasy Mini
kit (Qiagen) including DNase treatment. Typically,
1.0mg total RNA was reverse-transcribed using the
ThermoScript RT-PCR System (Invitrogen) or Revertra
Ace -a- (TOYOBO) with a 1:1 mixture of oligo dT and
random hexamer as primers. Minigene fragments were
ampliﬁed by PCR using a ﬂuorescein isothiocyanate
(FITC)-labeled forward primer for the 30 region of the
EGFP sequence (FITC-GFP-Fw) and a gene-speciﬁc
reverse primer (Clcn1-Rv for Clcn1 or CLCN1-Rv for
CLCN1 Supplementary Table S1). For Tpm2-based
minigenes, primers FITC-GFP-Fw and Tpm2-ex2-
splicing-Rv2 were used for ampliﬁcation. PCR products
were resolved by 2.0–2.5% agarose gel electrophoresis. By
sampling at multiple cycles, the cycle numbers of PCR
were adjusted such that the ampliﬁcation was within the
logarithmic phase. The ﬂuorescence of PCR products was
captured and visualized by LAS1000 or LAS3000
(FUJIFILM). The intensity of band signals was quantiﬁed
using Multigauge software (FUJIFILM). The ratio of
exon 7A inclusion in Clcn1 and CLCN1 was calculated
as (7A inclusion)/(7A inclusion+7A skipping) 100.
Quantitative PCR
Gene-speciﬁc primers were designed using Primer Express
software (Applied BioSystems) and are listed in
Supplementary Table S3. These primer sets were mixed
with cDNA samples and Power SYBR Green PCR
Master Mix (Applied BioSystems). Real-time ampliﬁca-
tion and quantiﬁcation were performed using an
ABI7700 (Applied BioSystems) following the manufac-
turer’s protocol.
Gel shift analysis
GST and GST-MBNL1 were puriﬁed as described
previously (22). Oligo DNA templates corresponding to
Clcn1(473–518) (CTGCCCAGGCACGGTCTGCAACA
GAGAAGCACGACGGGCGAGGCAGCCCTATAGT
GAGTCGTATTACCCC), Clcn1(GAA) (CTGTTCTTC
TTCTTCCTGCAACAGAGAAGCACGACGGGCGA
GGCAGCCCTATAGTGAGTCGTATTACCCC), and
Clcn1(a504c) (CTGCCCAGGCACGGGCTGCAACAG
AGAAGCACGACGGGCGAGGCAGCCCTATAGTG
AGTCGTATTACCCC) were purchased from Invitrogen
and annealed with another DNA fragment for the T7
promoter (GGGGTAATACGACTCACTATAGGG).
Using this partial duplex as a template, we transcribed
RNA using T7 RNA polymerase (MEGAscript T7 kit;
Ambion). The RNA was puriﬁed by phenol–chloroform
extraction followed by ethanol precipitation. The puriﬁed
RNA was treated with alkaline phosphatase, then labeled
by T4 polynucleotide kinase in the presence of g-
32P-ATP.
The labeled RNA was puriﬁed using a Nucaway spin
column (Ambion). The procedures and reaction mixture
used in the gel shift analysis are described in our previous
report (22).
Ribonucleoprotein immunoprecipitation
Ribonucleoprotein immunoprecipitation (RIP) was per-
formed as described previously (42), with minor
modiﬁcations. The amount of co-precipitated minigene
Nucleic Acids Research, 2009,Vol.37, No. 19 6479RNA was quantiﬁed by SYBR green-based Quantitative
PCR (qPCR) using the primers listed in Supplementary
Table S3. The procedure is described in the Supple-
mentary ‘Materials and Methods’ section.
RESULTS
MBNL and CELF proteins regulate the inclusion of
Clcn1 exon 7A
To examine whether the MBNL and CELF family
proteins can regulate the splicing of Clcn1, we created a
minigene covering exons 6 to 7 of the mouse Clcn1 gene
(Figure 1A). It is important to note that because the inclu-
sion of exon 7A does not produce a premature termina-
tion codon in the context of our Clcn1 minigene, the
spliced products containing exon 7A are not substrates
of NMD. Thus, the minigene would provide more
faithful splicing patterns compared to the endogenous
Clcn1. We utilized non-muscle cell lines to minimize the
eﬀect of muscle-dependent backgrounds and focus on the
direct eﬀects of transgenes. When the Clcn1 minigene was
transfected into COS-7 cells, 45% of the spliced products
contained exon 7A (Figure 1B). Next we expressed myc-
tagged MBNL or CELF proteins with the Clcn1 minigene
and examined the patterns of Clcn1 splicing. The
expressions of MBNL and CELF proteins were conﬁrmed
by Western blot analysis using an anti-myc antibody
(Supplementary Figure S6A). All three MBNL proteins
strongly repressed exon 7A inclusion (Figure 1B). In
contrast, CELF3, CELF4, CELF5 and CELF6 proteins
signiﬁcantly promoted the inclusion of 7A (Figure 1B).
Remarkably, CUG-BP and ETR-3 did not alter the
ratio of exon 7A inclusion (Figure 1B). These two
proteins increased the unspliced product and reduced the
spliced products with or without exon 7A (Figure 1C).
CELF4 and expanded CUG repeats act antagonistically
against MBNL1 in the splicing regulation of Clcn1
We investigated whether CELF proteins can antagonize
the eﬀect of MBNL1. Among CELF proteins that
promoted exon 7A inclusion in Clcn1, CELF4 was used
for the following analyses because this protein is expressed
in muscle (26,43). CELF4 and two other muscle-expressed
CELF proteins, CUG-BP and ETR-3, were co-transfected
with MBNL1, as well as the Clcn1 minigene. As shown in
Figure 2A, CELF4 increased the ratio of exon 7A in a
dose-dependent manner (lanes 7 and 8), whereas CUG-
BP or ETR-3 did not (lanes 3–6). When MBNL1 was
titrated in the presence of CELF4, a decrease in exon
7A inclusion was observed, depending on the dosage of
MBNL1 (Figure 2A, lanes 9–11). These results demon-
strate that MBNL1 and CELF4, but not CUG-BP or
ETR-3, can regulate Clcn1 exon 7A splicing in an antag-
onistic manner.
We also examined DMPK constructs harboring either
CTG18 (DM18) or interrupted CTG480 (DM480) in the
30-UTR. When these constructs were expressed with the
Clcn1 minigene, DM480 increased exon 7A inclusion,
whereas DM18 showed little eﬀect (Figure 2B, left).
These constructs were next expressed in the presence of
MBNL1. As shown previously, MBNL1 alone strongly
repressed the inclusion of exon 7A. DM480 reversed the
repression of exon 7A inclusion by MBNL1, whereas
DM18 did not (Figure 2B, right). Thus, expanded CUG
repeats can antagonize the eﬀect of MBNL1 on Clcn1
splicing.
Finally, we performed knockdown experiments using
vector-based RNAi to examine whether the regulation of
Clcn1 splicing is dependent on the dose of endogenous
MBNL1 or CUG-BP. The RNAi vector used here
expresses an artiﬁcial microRNA that is exactly comple-
mentary to a region of its target gene, leading to degrada-
tion of the target mRNA. For RNAi experiments,
we utilized Neuro2a and HeLa cells rather than COS-7
because of the availability of cDNA sequence information
essential for the design of microRNA. First, the over-
expression of MBNL1 in Neuro2a cells strongly repressed
the inclusion of exon 7A as in COS-7 cells (M, Figure 2C).
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Figure 1. Splicing regulation of MBNL and CELF proteins. (A)
Structure of chloride channel minigenes. Both human CLCN1/ClC-1
and mouse Clcn1 minigenes were subcloned between the BglII and
SalI sites of pEGFP-C1. Black boxes represent exons of the minigenes.
Arrows indicate the position of primers used in the splicing assays.
Exon 6B is a human-speciﬁc exon and is absent in Clcn1.( B)
Splicing regulation of Clcn1 by MBNL and CELF proteins.
Representative results of cellular splicing assays using the Clcn1
minigene in COS-7 cells. The upper bands correspond to a splice
product containing exon 7A, whereas lower bands correspond to a
splice product lacking exon 7A. Bar chart shows quantiﬁed results of
exon 7A inclusion (mean SD, n=3). Statistical signiﬁcance was
analyzed by analysis of variance (ANOVA) and Dunnett’s multiple
comparisons. All MBNL proteins and CELF proteins except for
CUG-BP and ETR-3 showed signiﬁcant diﬀerences ( P<0.0001)
compared to the empty vector. (C) CUG-BP and ETR-3 increased an
unspliced product of the Clcn1 minigene. Structures of PCR products
are indicated.
6480 Nucleic Acids Research, 2009, Vol. 37,No. 19An RNAi vector miMbnl1-146 was eﬀective in reducing
both Mbnl1 and Mbnl2 and increased the inclusion of
Clcn1 exon 7A compared to a control vector miLuc-200
(Figure 2C and Supplementary Figure S1). Another RNAi
vector, miMbnl1-236, also increased exon 7A inclusion
(data not shown). We also used HeLa cells for RNAi
experiments and found that the knockdown of MBNL1
resulted in an increase in exon 7A inclusion (Supple-
mentary Figure S2). Therefore, the splicing of Clcn1
exon 7A is regulated by MBNL in a dose-dependent
manner. In contrast, an eﬀective RNAi vector targeting
endogenous Cugbp1, miCugbp1-559, did not alter exon
7A splicing (Figure 2C and Supplementary Figure S1).
We were not able to conﬁrm the knockdown of
endogenous Etr-3/Cugbp2 and Celf4 because of very low
or undetectable endogenous expression in the cell lines
used in this study (data not shown); thus, the RNAi of
Etr-3 and Celf4 was not tested in the splicing analysis.
Involvement of the exon 7A sequence in the splicing
regulation by MBNL1
To understand the mechanism by which MBNL1 represses
the inclusion of Clcn1 exon 7A, we tried to deﬁne the
regions of the Clcn1 minigene that are responsive to
MBNL1. For this purpose, we examined a series of
Clcn1deletion mutants lacking a region in either introns
6o r7 A( 1–9, Figure 3A). As shown in Figure 3B,
deletions in intron 6 altered the basal splicing pattern.
For example, the 1 mutant exhibited increased inclusion
of exon 7A, suggesting the presence of an element in the
deleted region that represses exon 7A inclusion. However,
this mutant and the other intron 6 mutants (2–5) were
strongly repressed by MBNL1 (Figure 3B, upper panel).
Similarly, the series of intron 7A mutants did not lose
responsiveness to MBNL1 (6–9, Figure 3B). Thus,
large portions of these intronic regions could be
excluded from the region critical for responsiveness to
MBNL1.
Next we examined another series of deletion mutants
(Figure 4A, left). When minigene 6-7A was expressed
with the empty vector, both spliced and unspliced
products were observed (Figure 4A). Co-expression with
MBNL1 resulted in the repression of splicing (Figure 4A).
In the case of 7A-7, the expression of MBNL1 did not
cause a signiﬁcant change compared to that of the
empty vector (Figure 4A). To examine whether the
responsiveness of 6-7A was dependent on the sequence
of exon 7A, we analyzed the 6/7 mutant, in which the
sequence of exon 7A was virtually replaced with that of
exon 7. Interestingly, this replacement completely abol-
ished the responsiveness to MBNL1 (Figure 4A, right
panels). The observed loss of response in the 6/7 mutant
was not due to ineﬃcient basal splicing of exon 7, because
replacement of the ﬁrst 12nt of exon 7 in the 6/7 mutant
with an exonic-splicing enhancer (ESE) markedly
increased the spliced products but did not improve the
responsiveness to MBNL1 (Supplementary Figure S3).
Thus, exon 7A should contain at least part of the
MBNL1-responsive region. In addition, intron 6 alone
was insuﬃcient for response to MBNL1. To further
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MBNL1 or MBNL1 plus CELF protein into COS-7 cells. Upper
panel: lane 1, the pattern of empty vector-transfected cells; lanes 2–8,
a constant amount of MBNL1-encoding vector and increasing amounts
of one of the CELF-encoding vectors were co-transfected at ratios of
1:0 (lane 2), 1:1 (lanes 3, 5 and 7) and 1:3 (lanes 4, 6 and 8). Lower
panel: similarly, a CELF4-encoding vector and MBNL1-encoding
vector were transfected at ratios of 1:0 (lane 9), 1:1 (lane 10) and
1:3 (lane 11). The total amount of transfected plasmids was held
constant by adjusting the amounts of empty vector. (B) Eﬀects of an
expanded CUG repeat on the chloride channel splicing. Clcn1 minigene
was transfected with an expression vector of DMPK harboring a
normal (DM18) or expanded (DM480) CTG repeat (left panel).
Either normal or expanded DMPK vector was co-transfected with
MBNL1 and the Clcn1 minigene, and the splicing patterns were
analyzed (right panel). (C) Results of Clcn1-splicing assays in
Neuro2a cells. MBNL1-mediated repression of exon 7A inclusion
in Neuro2a cells (left). ‘V’ and ‘M’ indicate empty vector and
MBNL1, respectively. Note that the basal inclusion of exon 7A in
Neuro2a cells was higher than that in COS-7 cells. Clcn1-splicing reg-
ulation was aﬀected by RNAi of Mbnl1 but not Cugbp1 in Neuro2a
cells (right). Bar chart shows the quantiﬁed results of exon 7A inclusion
(mean  SD, n=4). According to ANOVA and Dunnett’s test,
miMbnl1-146 induced a statistically signiﬁcant increase of exon 7A
compared to miLuc-200 ( P<0.0001), whereas miCugbp1-559 did not
(P=0.36).
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6-7A,a3 0 deletion of the 6-7A fragment containing only
30nt from the 50 part of exon 7A. This fragment was still
responsive to MBNL1 (Figure 4B). Finally, we tested a
minigene derived from 7A-7 that had exon 7 as well as the
preceding 52nt replaced by the corresponding region
of exon 7A (Figure 4C). This minigene, 7A/( 52)7A,
exhibited increased unspliced products upon MBNL1
expression, suggesting that the substituted fragment
could mediate the response to MBNL1 in a heterologous
context (Figure 4C). These results suggest the involvement
of a 50 portion of exon 7A (30nt), as well as its upstream
52-nt region in the MBNL1-mediated-splicing regulation,
at least in the context of the truncated minigenes.
A region around the 3’ splice site of exon 7A mediates
the splicing regulation of MBNL1
To further analyze the regions critical for exon 7A
splicing, we generated heterologous minigenes in which
the exon of interest was inserted in the context of consti-
tutive exons of mouse tropomyosin 2 (Tpm2), a gene
distinct from Clcn1. Clcn1 fragments covering 414–720
or 451–720, or a reference fragment covering Tpm2 exon
9 and its ﬂanking intronic regions, were inserted into
a Tpm2 fragment covering exons 1 to 2 (Figure 5A).
MBNL1 repressed Clcn1 exon 7A inclusion of the
heterologous minigenes, demonstrating that the inserted
fragments of Clcn1 were suﬃcient for response to
MBNL1 (Figure 5B). In contrast, MBNL1 showed little
eﬀect on the inclusion of Tpm2 exon 9 (Figure 5B). Next
we made an additional chimeric minigene derived from the
451–720 minigene by replacing a region derived from
intron 7A with a sequence derived from Tpm2 intron 9
(int6-ex7A-int9; Figure 5A). Although int6-ex7A-int9
was still responsive to MBNL1, another minigene
with a further replacement of exon 7A with Tpm2 exon
9 (int6-ex9-int9) exhibited only a slight response to
MBNL1 (Figure 5C). Thus, the exon 7A sequence was
essential for regulation by MBNL1. Furthermore, a
minigene with an intermediate replacement, 7A(30)-
ex9(40), in which the ﬁrst 30nt of the exon and its
upstream intronic region were derived from Clcn1, was
responsive to MBNL1 (Figure 5C). These results suggest
that a region covering a 30 portion of intron 6, as well as
the ﬁrst 30nt of exon 7, can mediate splicing regulation by
MBNL1. This is consistent with the results of the
truncated minigenes displayed in Figure 4.
We also tested several minigenes to identify the region
of Clcn1 responsive to CELF4. Interestingly, CELF4 did
not increase the exon 7A inclusion of the 414–720 con-
struct, which was responsive to MBNL1 (Figure 5B and
D). However, minigenes covering 89–720 and 181–720,
but not 414–1050, increased the inclusion of exon 7A
upon CELF4 overexpression (Figure 5D and data not
shown). Therefore, an element responsive to CELF4 was
located in the region of 181–413, which was distinct from
the regions responsive to MBNL1 identiﬁed previously.
Lastly, we tested the 4 mutant that lacks the putative
responsive region for CELF4 (Figure 3A). CELF4 did
not promote exon 7A inclusion of 4 (Figure 5E). Thus,
181–413 was essential for the regulation of exon 7A
by CELF4.
MBNL1 binds directly to the transcript of the Clcn1
minigene
We next examined whether MBNL1 associates with
transcripts of Clcn1 in cells. In a ribonucleoprotein
immunoprecipitation (RIP) analysis (42), intracellular
RNA–protein complexes were reversibly ﬁxed with
paraformaldehyde and then co-immunoprecipitated.
Fixation allowed for stringent washing of immunopre-
cipitates to exclude post-lysis association between RNA
and proteins. We utilized a Neuro2a cell line stably
expressing EGFP-fused MBNL1. This cell line exhibited
a lower basal inclusion of exon 7A of endogenous Clcn1
compared to normal Neuro2a cells (Supplementary
Figure S5). EGFP-MBNL1 was precipitated by beads
pretreated with anti-GFP antibody or rabbit IgG. RNA
fragments derived from speciﬁc regions of endogenous
Clcn1 in the precipitates were detected by quantitative
PCR. The Association of Clcn1 intron 6 and EGFP-
MBNL1 was detected only when immunoprecipitated by
anti-GFP antibody (Figure 6A, left). Importantly, this
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6482 Nucleic Acids Research, 2009, Vol. 37,No. 19association was speciﬁc because intron 6 was highly
enriched compared to other Clcn1 regions (Figure 6A,
right).
In the results described previously, a region around
the boundary of intron 6 and exon 7A was suggested to
play an important role in the response to MBNL1
(Figures 4 and 5C). Previously, it was reported that
MBNL1 prefers mismatch-containing double-stranded
structures (22,44,45). It is interesting that a region
around the 30 splice site of exon 7A (corresponding to
473–518) was predicted to form a hairpin structure by
Mfold (http://www.bioinfo.rpi.edu/applications/mfold;
Figure 6B; 46). We examined whether MBNL1 can
bind to this fragment, Clcn1(473–518), by gel shift
analysis. GST-fused MBNL1, but not GST alone, bound
to the Clcn1 fragment in a dose-dependent manner
(Figure 6C). GST-MBNL1 exhibited an apparently
lower aﬃnity for Clcn1(GAA), a mutant RNA in which
the ﬁrst 12nt of exon 7A were substituted by a (GAA)4
repeat (Figure 6C). Therefore, the sequence at the 50 end
of exon 7A contributes to the binding of MBNL1.
The 5’ end of exon 7A contains an ESE
Region 451–533 of Clcn1 consistently accounted for
the responsiveness to MBNL1 in multiple contexts
(Figures 4B and 5C). We noticed that this region
contained a YGCU(U/G)Y motif (Y: C or U;
Figure 7A), which has been reported as a binding consen-
sus sequence for MBNL1 (24). A mutant minigene con-
taining a mutation of this motif (but otherwise the same as
the full-length minigene) was examined in a splicing assay
(Mut 1, Figure 7A). Mut1 was fully responsive to MBNL1
as well as to CELF4 (Figure 7B). Thus, this motif itself
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Nucleic Acids Research, 2009,Vol.37, No. 19 6483was dispensable for the response to MBNL1 in exon 7A
splicing.
The preceding analyses suggested that the 50 end of
exon 7A is involved in the responsiveness to MBNL1
(Figures 4B and 5C). To characterize the role of this
region, we ﬁrst examined a minigene lacking the ﬁrst
15nt of exon 7A (Mut 2, Figure 7A). Unexpectedly, this
deletion resulted in the complete exclusion of exon 7A,
even without MBNL1 overexpression (Figure 7B),
indicating the presence of an ESE in this region that is
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tailed t-test). (E) Splicing analysis of the 4 mutant minigene and CELF4. The structure of 4 is described in Figure 3A. Splicing analysis results are
shown as in D. CELF4 did not signiﬁcantly alter the splicing of 4( P=0.97, n=3, two-tailed t-test).
6484 Nucleic Acids Research, 2009, Vol. 37,No. 19essential for the basal inclusion of exon 7A. We further
tested 6-nt deletions in either the 50 or 30 parts of the 15-nt
region (Mut 3 and Mut 4, Figure 7C). Only Mut 3
exhibited complete exon 7A skipping like Mut 2
(Figure 7C). Direct comparison of the sequences of Mut
3 and Mut 4 showed that 5nucleotides diﬀered between
these mutants (Figure 7D, upper). We then introduced
substitutions of these nucleotides into the full-length
minigene (Mut 5a and Mut 5b, Figure 7D). Both Mut
5a and 5b exhibited reduced basal inclusion of exon 7A,
with a stronger eﬀect from Mut 5a (Figure 7D). Finally,
we tested two point mutants, a504c and t512g, to deﬁne
the region of the ESE. Whereas the t512g mutation had no
eﬀect on the basal splicing of exon 7A, mutant a504c
totally disrupted the inclusion of exon 7A (Figure 7D).
Because Mut 5b (c511a and t512g), but not t512g alone,
showed a reduction in exon 7A inclusion, mutation c511a
should be critical for exon 7A inclusion. GST-MBNL1
bound to an RNA containing the a504c mutation with a
lower aﬃnity compared to Clcn1(473–518) (Figure 6C),
suggesting that the strong repressive eﬀect of a504c was
due to the direct disruption of the ESE rather than a
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precipitated with anti-GFP antibody or IgG was reverse-transcribed. The amount of Clcn1 (pre-)mRNA was quantiﬁed by real-time quantitative
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structure of the fragment Clcn1(473–518) (lower). (C) Binding between GST-MBNL1 and Clcn1(473–518) or its mutants was examined by gel shift
analysis (left).
32P-labeled probes were incubated with or without GST-MBNL1 (0.225, 0.45, 0.9, 1.8mM) or GST (1.8mM). The reaction mixture was
separated by native PAGE and visualized by autoradiography. Structure of probes used in gel shift analysis (right). In the Clcn1(GAA) mutant, the
ﬁrst 12nt of exon 7A are substituted by (GAA)4 repeats. The Clcn1(a504c) mutant contains a point mutation of the ﬁrst nucleotide of exon 7A but is
otherwise the same as Clcn1(473–518).
Nucleic Acids Research, 2009,Vol.37, No. 19 6485hypersensitivity to MBNL1. Thus, we concluded that the
8nt at the 50 end of exon 7A, 504–511, contain an ESE
essential for the basal inclusion of exon 7A.
DISCUSSION
CLCN1/Clcn1 splicing is a key event in DM. Although the
misregulation of splicing has been well established as a
characteristic abnormality of DM, few misregulated
genes have a clear causal relationship to symptoms of
DM. Clcn1 misregulation can account for myotonia in
DM model mice (38,47,48). As demonstrated recently,
the skipping of exon 7A induced by AON reversed the
myotonic phenotype of DM model mice (38), making
CLCN1 splicing a promising target for therapeutic
approaches. Understanding Clcn1/CLCN1 splicing
would aid in the design of rational strategies for correcting
CLCN1 expression to perhaps prevent myotonia. In
addition, the identiﬁcation of molecular pathways caus-
ative of Clcn1 missplicing is important for the evaluation
or interpretation of DM model mice. Besides the afore-
mentioned model mice, myotonic phenotypes are observed
in several other mouse models (49–52). It is unclear
whether the loss of MBNL function can explain all of
these myotonic mice (51). In these contexts, a Clcn1
minigene should be useful for identifying and charac-
terizing the factors that modulate the splicing pattern of
Clcn1. Indeed, we have identiﬁed multiple determinants
for the regulation of exon 7A splicing using a Clcn1
minigene and its derivatives.
MBNL proteins regulate Clcn1 exon 7A
Previous genetic studies have indicated the involvement of
MBNL proteins in the regulation of Clcn1 splicing. The
loss of either Mbnl1 or Mbnl2 can cause myotonia in mice,
whereas overexpression of Mbnl1 rescues the myotonic
phenotype in HSA
LR mice (13,23,37). However, these
studies have not excluded the indirect involvement of
MBNL proteins such that they regulate muscle diﬀerenti-
ation or maintenance, which in turn alters the activity of
other splicing factors to result in altered Clcn1 splicing.
Indeed, exon 7A of Clcn1 is regulated through muscle
development and is preferentially included in neonatal
muscle but not in adult muscle (16,47). Here, we have
demonstrated that the splicing regulation of Clcn1 exon
7A by MBNL1 was observed in COS-7, HeLa and
Neuro2A cell lines (Figures 1 and 2 and Supplementary
Figure S2). Thus, the regulation of exon 7A can be deter-
mined directly by the expression level of MBNL proteins,
even without the context of muscle cells. The inclusion of
exon 7A was repressed by the overexpression of MBNL
proteins but increased by their knockdown (Figures 1
and 2). In addition, MBNL1 associated with the pre-
mRNA of Clcn1 in the cell (Figure 6A), and direct
binding between MBNL1 and an RNA fragment of
Clcn1 was veriﬁed in vitro (Figure 6C). These results are
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6486 Nucleic Acids Research, 2009, Vol. 37,No. 19consistent with the model that MBNL proteins direc-
tly regulate CLCN1/Clcn1 and that the loss of
MBNL function leads to CLCN1/Clcn1 misregulation in
DM.
Differential effects of CELF proteins on Clcn1 splicing
In contrast to MBNL proteins, CELF3/4/5/6 promoted
increased inclusion of exon 7A of mouse Clcn1
(Figure 1B). Among these CELF proteins, CELF4 is
expressed in a wide variety of tissues, including muscle
(26,43). Although mice deﬁcient in Celf4 have been
reported to manifest a complex seizure phenotype (53),
the physiological function of CELF4 is largely unclear.
Although an elevation of CUG-BP and ETR-3 proteins
was observed in DM1 patients, the other CELF proteins
have not been well characterized. The expression level,
intracellular localization, and activity of CELF4 (and
CELF3/5/6) should be investigated in the context of
DM. Although Clcn1 is enriched in muscle, it is expressed
in other tissues including brain even at a low level (data
not shown). Because some CELF proteins are enriched in
the brain (43), they might play a role in keeping Clcn1
expression at a low level in the brain or possibly other
tissues through a splicing-mediated regulation of
expression.
In contrast, CUG-BP and ETR-3 did not directly
change the ratio of exon 7A inclusion in our mouse
Clcn1 minigene (Figures 1B and 2C). This was unexpected
because the inclusion of exon 7A has been reported to be
increased in CUG-BP transgenic mice (33). It is possible
that the regulation of exon 7A by CUG-BP is dependent
on some speciﬁc cellular conditions and/or the genomic
context of Clcn1 that is missed in the minigene. Alterna-
tively, the transgenic mouse might involve indirect or
secondary eﬀects of long-term CUG-BP overexpression.
Nevertheless, our results might be compatible with a role
of CUG-BP or ETR-3 in the misregulation of mouse
Clcn1, as the overexpression of these proteins could
reduce spliced Clcn1 products and increase intron reten-
tion (Figure 1C). It should be noted, however, that both
CUG-BP and ETR-3 increase neither the inclusion of
exon 7A nor the unspliced product in the human
CLCN1 minigene in our preliminary results (Kino et al.,
unpublished data). The determinants of the diﬀerence
between human and mouse minigenes are currently
under investigation. Our results also revealed a functional
heterogeneity among CELF proteins. The Clcn1 minigene
would allow us to determine the cause of the diﬀerence in
the eﬀects of CELF proteins on exon 7A inclusion.
Multiple factors involved in the regulation of Clcn1
exon 7A splicing
To clarify the regulatory mechanism of exon 7A splicing,
we analyzed a series of Clcn1 mutant minigenes. We found
that the regulation of exon 7A by MBNL1, as well as their
binding, was at least partly mediated by the sequence
of exon 7A itself. Furthermore, the MBNL-responsive
regions were mapped roughly to a boundary region of
exon 7A and its ﬂanking intronic sequence, or 451–533.
In the previous examples, MBNL1 regulated its target
exons through intronic sequences of cTNT, TNNT3, and
SERCA1 (24,45,54). In contrast, neither intron 6 nor 7A
of Clcn1 was suﬃcient for response to MBNL1
(Figures 4A and 5C). Our results suggest that not only
intronic but also exonic sequences should be considered
for analyses such as genome-wide identiﬁcation of the
MBNL splicing targets.
We found an ESE located at the 50 end of exon 7A
(504–511) that was essential for the basal inclusion of
exon 7A (Figure 7). The nucleotide sequence of this ESE
is completely conserved in human CLCN1. In general,
ESEs are important motifs for both constitutive and alter-
native splicing and are bound by SR proteins that enhance
the recognition of an exon and promote splicing (55,56).
The ESEﬁnder algorithm (http://rulai.cshl.edu/tools/
ESE/; 57) predicted that the candidate region overlaps
with potential recognition sites for multiple SR proteins
(data not shown). However, the prediction pattern went
unchanged even when a critical mutation (a504c) was
introduced. Interestingly, the ESE in the 50 end of exon
7A overlaps with the region targeted by the AON eﬀective
against myotonia in mouse models (38). Hybridization of
the AON may prevent the functioning of not only the
polypyrimidine (PY) tract and 30 splice site but also the
ESE, leading to eﬃcient exon 7A skipping.
Previously, we have suggested double-stranded RNA
with mismatches as putative MBNL1-binding targets
(22), which was supported by recent analyses directly
demonstrating that stem-loop structures with a pyrimidine
mismatch are binding sequences of MBNL1 and mediate
its splicing regulation (44,45). In contrast, YGCU(U/G)Y
motifs have been reported as binding sites for MBNL1
in cTNT and SERCA1 (24,54). In the case of cTNT,
however, the YGCU(U/G)Y motifs were later shown to
be part of a stem-loop structure (44). Here, we found a
stem-loop structure in the junctional region between
intron 6 and exon 7A as a candidate region for
MBNL1-binding. Indeed, this fragment could bind with
recombinant MBNL1 (Figure 6C). Furthermore, substitu-
tions that alter this hairpin region impaired the respon-
siveness to MBNL1 (Figures 4A, 5C, Supplementary
Figure 3) and the binding of RNA to MBNL1
(Figure 6C). Interestingly, this hairpin region overlaps
with splicing signals, such as the PY tract, 30 splice site
and the ESE described previously. In particular, the ESE
overlaps with an RNA region essential for eﬃcient
binding to MBNL1 (Figures 6C and 7). Therefore, one
possible explanation of how MBNL1 acts on exon 7A
splicing is that MBNL1 binds to the hairpin structure
and inhibits the access of splicing factors to these
splicing signals, like the AON described previously. The
Clcn1(GAA) mutant exhibited residual binding to
MBNL1 (Figure 6C). This might be explained by the
presence of a YGCU(U/G)Y motif in intron 6.
Lastly, the region of Clcn1 that mediates the eﬀect of
CELF4 was located within 181–413 (Figure 5D and E),
which was not necessary for the regulation by MBNL1
(Figure 3). Therefore, antagonistic regulation by MBNL1
andCELF4 is mediated by distinct regions of the minigene.
This is similar to the case of cTNT exon 5, which is
regulated by CUG-BP and MBNL1 through distinct
Nucleic Acids Research, 2009,Vol.37, No. 19 6487binding motifs (24). Because the 4 mutant exhibited a
higher basal inclusion of exon 7A (Figure 5E), the
deleted region (181–413) may contain an element that
represses exon 7A inclusion. Perhaps CELF4 might antag-
onize this repressive element, which might explain how the
eﬀect of CELF4 was lost in the case of the 4 mutant.
Our current model for Clcn1 regulation is depicted in
Figure 8. Alternative splicing of exon 7A can be regulated
by MBNL and by certain CELF proteins, such as CELF4.
Expanded CUG/CCUG repeats may deplete MBNL and
decrease the probability of binding between MBNL and
the pre-mRNA of Clcn1. The ESE located at the 50 end
of exon 7A and the ﬂanking splicing signals might be
common targets of MBNL and the previous AON.
Taken together, our results reveal novel regulatory
properties of MBNL and CELF proteins and provide a
molecular basis for the mechanism of splicing regulation
of Clcn1, which might underlie rational therapeutic
strategies targeting myotonia in DM.
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